scholarly journals The Relevance of the UPS in Fatty Liver Graft Preservation: A New Approach for IGL-1 and HTK Solutions

2017 ◽  
Vol 18 (11) ◽  
pp. 2287 ◽  
Author(s):  
Arnau Panisello-Roselló ◽  
Eva Verde ◽  
Mohamed Amine Zaouali ◽  
Marta Flores ◽  
Norma Alva ◽  
...  
2021 ◽  
Vol 22 (10) ◽  
pp. 5332
Author(s):  
Raquel G. Bardallo ◽  
Rui Teixeira da Silva ◽  
Teresa Carbonell ◽  
Emma Folch-Puy ◽  
Carlos Palmeira ◽  
...  

The total damage inflicted on the liver before transplantation is associated with several surgical manipulations, such as organ recovery, washout of the graft, cold conservation in organ preservation solutions (UW, Celsior, HTK, IGL-1), and rinsing of the organ before implantation. Polyethylene glycol 35 (PEG35) is the oncotic agent present in the IGL-1 solution, which is an alternative to UW and Celsior solutions in liver clinical transplantation. In a model of cold preservation in rats (4 °C; 24 h), we evaluated the effects induced by PEG35 on detoxifying enzymes and nitric oxide, comparing IGL-1 to IGL-0 (which is the same as IGL-1 without PEG). The benefits were also assessed in a new IGL-2 solution characterized by increased concentrations of PEG35 (from 1 g/L to 5 g/L) and glutathione (from 3 mmol/L to 9 mmol/L) compared to IGL-1. We demonstrated that PEG35 promoted the mitochondrial enzyme ALDH2, and in combination with glutathione, prevented the formation of toxic aldehyde adducts (measured as 4-hydroxynonenal) and oxidized proteins (AOPP). In addition, PEG35 promoted the vasodilator factor nitric oxide, which may improve the microcirculatory disturbances in steatotic grafts during preservation and revascularization. All of these results lead to a reduction in damage inflicted on the fatty liver graft during the cold storage preservation. In this communication, we report on the benefits of IGL-2 in hypothermic static preservation, which has already been proved to confer benefits in hypothermic oxygenated dynamic preservation. Hence, the data reported here reinforce the fact that IGL-2 is a suitable alternative to be used as a unique solution/perfusate when hypothermic static and preservation strategies are used, either separately or combined, easing the logistics and avoiding the mixture of different solutions/perfusates, especially when fatty liver grafts are used. Further research regarding new therapeutic and pharmacological insights is needed to explore the underlying mitochondrial mechanisms exerted by PEG35 in static and dynamic graft preservation strategies for clinical liver transplantation purposes.


2013 ◽  
Vol 55 (1) ◽  
pp. 65-78 ◽  
Author(s):  
Mohamed Amine Zaouali ◽  
Eleonora Boncompagni ◽  
Russel J. Reiter ◽  
Mohamed Bejaoui ◽  
Isabel Freitas ◽  
...  

2017 ◽  
Vol 23 (23) ◽  
pp. 4211 ◽  
Author(s):  
Mohamed Amine Zaouali ◽  
Arnau Panisello-Roselló ◽  
Alexandre Lopez ◽  
Carlos Castro Benítez ◽  
Emma Folch-Puy ◽  
...  

2007 ◽  
Vol 39 (10) ◽  
pp. A37 ◽  
Author(s):  
E. Boncompagni ◽  
C. Guarnaschelli ◽  
V. Bertone ◽  
A. Ferrigno ◽  
F. Carlucci ◽  
...  

2021 ◽  
Author(s):  
Patricia Ruiz ◽  
Andres Valdivieso ◽  
Ibone Palomares ◽  
Mikel Prieto ◽  
Alberto Ventoso ◽  
...  

Author(s):  
Manon Allaire ◽  
Hélène Gilgenkrantz

Abstract Alcoholic and non-alcoholic fatty liver diseases are the leading causes of cirrhosis in Western countries. These chronic liver diseases share common pathological features ranging from steatosis to steatohepatitis. Fatty liver is associated with primary liver graft dysfunction, a higher incidence of complications/mortality after surgery, in correlation with impaired liver regeneration. Liver regeneration is a multistep process including a priming phase under the control of cytokines followed by a growth factor receptor activation phase leading to hepatocyte proliferation. This process ends when the initial liver mass is restored. Deficiency in epidermal growth factor receptor (EGFR) liver expression, reduced expression of Wee1 and Myt1 kinases, oxidative stress and alteration in hepatocyte macroautophagy have been identified as mechanisms involved in the defective regeneration of fatty livers. Besides the mechanisms, we will also discuss in this review various treatments that have been investigated in the reversal of the regeneration defect, for example, omega-3 fatty acids, pioglitazone, fibroblast growth factor (FGF)19-based chimeric molecule or growth hormone (GH). Since dysbiosis impedes liver regeneration, targeting microbiota could also be an interesting therapeutic approach.


2017 ◽  
Vol 23 (9) ◽  
pp. 1171-1185 ◽  
Author(s):  
Shinya Okumura ◽  
Tadahiro Uemura ◽  
Xiangdong Zhao ◽  
Yuki Masano ◽  
Tatsuaki Tsuruyama ◽  
...  

2014 ◽  
Vol 98 ◽  
pp. 707
Author(s):  
J. Wiederkehr ◽  
M. Igreja ◽  
M. Nogara ◽  
N. Goncalves ◽  
M. Godoy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document